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Abstract
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a prokaryotic adaptable immune mechanism
used by many bacteria and archaea to protect themselves from foreign nucleic acids. This complex system can
recognize and cut non-self DNA in order to provide the prokaryotic organisms a strong defense against foreign
viral or plasmid attacks and make the cell immune from further assaults. Today, it has been adapted to be used in
vitro and in vivo in eukaryotic cells to perform a complete and highly selective gene knockout or a specific gene
editing. The ease of use and the low cost are only two features that have made it very popular among the
scientific community and the possibility to be used as a clinical treatment in several genetic derived pathologies
has rapidly spread its fame worldwide. However, CRISPR is still not fully understood and many efforts need to be
done in order to make it a real power tool for the human clinical treatment especially for oncological patients.
Indeed, since cancer originates from non-lethal genetic disorders, CRISPR discovery fuels the hope to strike tumors
on their roots. More than 4000 papers regarding CRISPR were published in the last ten years and only few of them
take in count the possible applications in oncology. The purpose of this review is to clarify many problematics on
the CRISPR usage and highlight its potential in oncological therapy.
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Background
The birth of CRISPR
CRISPR (Clustered Regularly Interspaced Short
Palindromic Repeats) system is a prokaryotic adaptable
immune mechanism used by many bacteria and archaea
to protect themselves from foreign nucleic acids, such as
viruses or plasmids [1–4]. The first time CRISPR was ever
described was from Osaka University researcher Yoshi-
zumi Ishino in 1987 [5], who accidentally cloned part of a
CRISPR together with the iap gene, his target of interest
and its function was not cleared at the time. Later on, in
1993 researchers of Mycobacterium tuberculosis in the
Netherlands published two articles about a repeat cluster
in this bacterium that was named “direct repeat (DR)” re-
gion. These researchers recognized the diversity in the
composition of repeat cluster spacers [6]. At the same
time, the later called CRISPR was also observed in the ar-
chaeal organism Haloferax mediteranii and its function
was studied by Francis Mojica at the University of Ali-
cante, Spain [7]. Anyway, the real begin of CRISPR history,
is in 1997 when Ruud Jansen at the University of Utrecht,
recognized a similarity among the structure of the iap re-
peats of E. coli, the DR region of M. tuberculosis and the
repeat cluster of H. mediteranii, defining these features as
members of the CRISPR family. From that discovery nu-
merous CRISPR’s were recognized in the whole genomes
of bacteria and archaea that were published, indicating
that CRISPR is a universal feature of prokaryotes. A major
addition to the understanding of CRISPR came with the
observation that the repeat cluster was accompanied in
the prokaryotic genomes by a set of highly conserved
homologous genes, the CRISPR associated or Cas genes.
Four Cas genes (Cas 1 to 4) were recognized and the Cas
proteins showed helicase and nuclease motifs, suggesting
a dynamic role of these proteins in the CRISPR machin-
ery. For many years CRISPR remain a “mystery item” until
2005, when three independent research groups showed
that some CRISPR spacers are derived from phage DNA
and extrachromosomal DNA such as plasmids [8–10]. In-
deed, the spacers are only fragments of DNA gathered
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from viruses that previously tried to attack the cell. The
source of the spacers was a sign that the CRISPR/Cas sys-
tem could have a role in an adaptive immunity in bacteria.
In 2008, Brouns et al. identified a complex of Cas protein
that in E. coli cut the CRISPR RNA within the repeats into
spacer-containing RNA molecules [11], which remained
bound to the protein complex. In the same year, Marraf-
fini [12] showed that a CRISPR sequence of Staphylococ-
cus epidermidis targeted DNA and not RNA to prevent
conjugation. A 2010 study provided direct evidence that
CRISPR-Cas cuts both strands of phage and plasmid DNA
in S. thermophiles [13]. In 2012 Jinek [14] showed that the
core CRISPR/Cas9 mechanism is based on a dual-RNA
structure that directs the Cas9 endonuclease to introduce
site-specific double-stranded breaks in target DNA. This
discovery broke up the old technology such as TALEN,
Meganucleases and ZFNs, demonstrating that the guide
RNA could be easily engineered as a single transcript to
target and cleave any dsDNA sequence of interest. We
had to wait until 2014 to see the first example of use as a
tool for editing the genome, when Hsu et al. [15] manipu-
lated the resistance of S. thermophilus to phage by adding
and deleting spacers whose sequence matched those
found in the phages tested. Finally, in 2015 there was the
first attempt in editing human embryos [16] showing that
even if promising, we are still far from any clinical use of
CRISPR technology in embryos, triggering also a contro-
versial ethical debate.
The mechanism of action
The CRISPR system can be found on both chromo-
somal and plasmid DNA. Type II CRISPR incorporate
sequences from invading DNA between CRISPR re-
peat sequences thanks to Cas1 and Cas2 [17]. These
regions that are complementary to the foreign DNA
are called Protospacers. Transcript from part of these
regions are processed into CRISPR RNAs (crRNAs)
and hybridizes with a second RNA called transactivat-
ing CRISPR RNA (tracrRNA) [18]. This complex of
crRNA and tracrRNA binds a nuclease and helicase
protein called Cas9. Protospacer-encoded portion of
the crRNA directs Cas9 to cleave complementary
target-DNA sequences, if they are adjacent to short
sequences known as protospacer adjacent motifs
(PAMs). PAMs are very important to the recognition
of self and non-self DNA because are presents only
in the foreign DNA sparing the CRISPR mechanism
to delete itself. Indeed, protospacer sequences incor-
porated into the CRISPR locus are not cleaved pre-
sumably because they are not next to a PAM
sequence. This prokaryotic system has been adapted
to be used in vitro, merging the crRNA with a part
of the tracrRNA in a hybrid called guide RNA
(gRNA). Twenty nucleotides at the 5’ end of the
gRNA (corresponding to the protospacer portion of
the crRNA) direct Cas9 to a specific target DNA site
using standard RNA-DNA complementarity Watson-
Crick base-pairing rules. The site to be cleaved must
lie immediately 5’ of a PAM sequence, although rec-
ognition at sites with alternate PAM sequences could
be possible, although at less efficient rates [19–21]
(Fig. 1). Cas9-induced double strand breaks (DSBs) are
commonly repaired exploiting the NHEJ (Non Homolo-
gous End Join) mediating indel mutations as well as indu-
cing HDR (Homologous Directed Repair) by providing
single-stranded oligonucleotide acting as a donor tem-
plate. In the error-prone NHEJ pathway, the ends of DSB
are processed by endogenous DNA repair machinery and
rejoined, which results in random indel mutations at the
site of junction which can result in the frameshifts within
the coding region of a gene and can cause the creation of
a premature stop codon, knocking out the target gene. Al-
ternatively, when a repair template in the form of a single-
stranded oligodeoxynucleotide (ssODN)is supplied, the
HDR pathway allows high fidelity and precise editing [22].
Cas9 variants
Cas9 is a bi-lobed architecture protein with the gRNA
nestled between the alpha-helical lobe and the nucle-
ase lobe. These two lobes are connected through a
single bridge helix. There are two main domains lo-
cated in the multi-domain nuclease lobe: the RuvC,
which shares an RNase H fold structure with other
nucleases in the retroviral integrase superfamily [23],
which cleaves the non-target DNA strand, and the
HNH nuclease domain, that has a ββα-metal fold that
comprises the active site, which cleaves the target
strand of DNA [24]. The gRNA base paired with tar-
get ssDNA is anchored by Cas9 as a T-shaped archi-
tecture. The nuclease also consists of a recognition
lobe (REC) that matches the target sequence in the
host DNA. Several Cas9 mutants including REC do-
main deletion and residues mutations in the bridge
helix (BH) domain have been tested to improve its ef-
ficiency and to find other useful “side effects”. REC
and BH mutants show lower or none activity com-
pared with wild type, which indicate these two do-
mains are crucial for the gRNA recognition and
stabilization of the whole complex. Normally Cas9
performs a double strand break in the target DNA
site, while introducing a D10A or H840A mutation
into the RuvC- or HNH-like nuclease domains results
in the generation of a single cut [25] (Fig. 2). These
mutants also known as Nickase have also been shown
to be useful for genome editing. Nickase cut either
the complementary or non-complementary DNA tar-
get strands, respectively, in vitro.
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Off target effect risks and possible solutions
Even if very efficient, this system is not completely im-
mune to errors, so understanding the possible weak
sides could be helpful to prevent all potential off-target
effects. Recently, a number of studies have examined
potential off-target sites that differ from one to six posi-
tions from the on-target site in human cells [26, 27]. To
prevent these effects, it has been suggested that higher
GC content at the RNA:DNA interface might potentially
help to stabilize binding the hybridization, indeed high
Fig. 1 Type II CRISPR mechanism of action. Foreign DNA is cut and acquired by Cas1 and 2 between CRISPR repeat sequences (a) forming PAMs.
Then a RNA Polymerase transcribes part of the CRISPR repeat and part of the PAM generating a crRNA (b) that hybridize with a tracrRNA and
reach a homologous target sequence on the genomic DNA (c). Cas9 performs a DSB that it is repaired with a NHEJ causing indel mutations and
so probably a premature stop codon (d)
Fig. 2 Cas9 structure. The alpha-helical lobe and the nuclease lobe composed by, RuvC and HNH domain. The D10A and the H840A mutations in
these last two domains cause the loss of ability to perform a DSB making only a single nick per strand. These particular Cas9 are commonly
called Nickases
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rates of mutagenesis have been observed for off-target
sites with as little as 30% matched GC content [24].
Moreover, we also do not know how genomic and/or
epigenomic context might affect the frequency of cleav-
age. Although some initial evidence suggests that DNA
methylation does not inhibit Cas9-based genome editing
[28], it seems plausible and likely that chromatin struc-
ture could play a role in off-target site accessibility. One
potential strategy to reduce off-target and improve spe-
cificity involves the use of paired nickases in which adja-
cent off-set nicks are generated at the target site using
two gRNAs and Cas9 mutant. Paired Cas9 nickases, tar-
geted to sites on opposite DNA strands separated by 4
to 100 bp, can efficiently introduce both indel mutations
and, in case a single-stranded DNA oligonucleotide
donor template is provided, can induce HDR events in
mammalian cells [29, 30]. However, the second gRNA
can itself induce its own range of off-target mutations in
the genome as multiple studies have shown that single
monomeric Cas9 nickases can function on their own to
induce indel mutations at certain genomic loci, perhaps
because an individual nick might be converted to a DSB
when a replication fork passes through the locus [31, 32].
The existence of these off-target effects and our inability
to identify these alterations on a genome-wide scale mean
that researchers need to account for the potentially con-
founding effects of these undesired mutations. The best
and easiest strategy to rule out off-target mutations is the
use of complementation, reintroducing a wild-type gene,
which can be used to confirm the effects of knockout. An-
other possibility is to use gRNAs targeted to different sites.
Presumably, each gRNA will be expected to have a differ-
ent range of off-target effects and therefore if the same
phenotype is observed with each of these different gRNAs
it would seem unlikely that undesired mutations are the
cause.
CRISPR delivery possibilities
There are several methods to deliver all the components
of CRISPR machinery. In cultured mammalian cells, can
be used electroporation, nucleofection and Lipofectamine-
mediated transfection of non-replicating plasmid DNA to
transiently express Cas9 and gRNAs. Lentiviral vectors
have also been used to constitutively express Cas9 and/or
gRNAs in cultured human and mouse cells with higher ef-
ficiency [33–35]. Another useful delivery system is com-
bining gRNA and an exogenous Cas9 conjugated with cell
penetrating peptides (CPP) or encapsulated in nanoparti-
cles [36, 37]. For most applications, transient expression
of gRNAs and Cas9 is typically sufficient to induce effi-
cient genome editing. Indeed, after expression and selec-
tion plasmid expressing CRISPR machinery is usually lost,
avoiding that extended persistence in the cell will lead to
increased frequencies of off-target mutations.
Clinical and therapeutically uses
The advent of CRISPR has not only marked a new era
for the in vitro genome editing, giving us a powerful tool
to better understand the fine mechanisms at the base of
molecular biology but has also revolutionized the “per-
sonalized” or “precise” medicine therapy. Many diseases
in fact, hide a genetic origin and following the central
dogma of molecular biology, we can precisely edit those
mutations that cause the disease to restore the expres-
sion of the “healthy” form of the protein. As recently re-
ported by three separate research groups [38–40], gene
therapy using CRISPR technology for Duchenne muscu-
lar dystrophy is ongoing clinical trials showing very posi-
tive results both in adult muscle differentiated cells and
muscle stem cells. CRISPR approach for treatment of
Cystic Fibrosis as well, despite being in its early stages, is
very promising. Indeed, stem cells can be corrected by
delivering the therapeutic agents into the airways or, al-
ternatively, generating CFTR-corrected stem respiratory
epithelial cells and subsequently be administered to the
patients [41]. Methods for efficient delivery and expres-
sion of CRISPR-Cas system components will undoubt-
edly need to be optimized for each particular cell-type
or organism to be modified. Collectively, these advances
will be important for research use and therapeutic appli-
cations. Strategies for shifting the balance away from
NHEJ-mediated indel mutations and toward HDR-
driven alterations remain a priority. Although high rates
of HDR can be achieved with the CRISPR and single-
stranded DNA oligonucleotides, competing mutagenic
NHEJ also occurs simultaneously. One of the drawbacks
to developing an approach to improve the HDR:NHEJ
ratio is that inhibition of NHEJ is likely to be poorly tol-
erated by most cells, given its central role in normal
DNA repair. For therapeutic applications seeking to ex-
ploit HDR, reduction or elimination of competing NHEJ
will be crucially important. Another promising therapy
is to eliminate viral infection from the host genome
using CRISPR. Human Papillomaviruses (HPVs) are
today the main responsible for cervical carcinoma and
anogenital cancers. Two research groups in 2014 used
for the first time CRISPR to induce indel mutations in
the viral genes encoding for E6 and E7 proteins in hu-
man cells [42, 43]. These proteins, inactivating respect-
ively p53 and pRb, drive infected cells to an abnormal
proliferation leading to tumor transformation. CRISPR
capability to perform a selective knock out of viral genes
is being use in Hepatitis B virus (HBV) as well as in
HPVs. Indeed, several researchers designed sgRNAs tar-
geting the HBV core and HBsAg proteins to reduce
HBV-related symptoms and to treat HBV-associated dis-
ease. The most recent one, is the approach used by Zhen
et al. [44] who targeted the HBsAg and HBx-encoding
region of HBV, both in vitro and in vivo. HBsAg levels
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in the cultures media of cells and in the sera of mice
were reduced as well as the HBV DNA levels and
HBsAg protein expression in mouse livers. Epstein-Barr
virus (EBV) is another etiologic agent capable to drive
cancer-leading mutations, causing the Burkitt’s lymph-
oma and the nasopharyngeal carcinoma. While Wang
and Quake designed several sgRNAs targeting the nu-
clear antigens EBNA1, EBNA3C and the latent mem-
brane protein 1 (LMP-1) [45], Yuen et al. [46] used two
sgRNAs targeting the promoter region of BART miRNA,
to reduce the proliferation and to promote the decline in
viral load as well as restoration of the apoptosis pathway
in infected cells. As demonstrated by Wang et al. [47],
Cas9 can knockout viral sequences of HIV-1 in mamma-
lian cells causing the activation of NHEJ repairing sys-
tem and generating some indel mutations that are
potentially lethal for the virus. So while in some cells the
virus is easily eradicated, in others some indel mutations
are refractory to recognition by the same gRNA as a re-
sult of changing the target DNA sequences, leading to
the emergence of replication competent viruses that are
resistant to Cas9/gRNA. More recently, Chaoran et al.
used an all-in-one adeno-associated virus (AAV) vector
to deliver multiplex sgRNAs targeting four different viral
structural genes and the Staphylococcus aureus-derived
Cas9, demonstrating that this strategy greatly reduces
the potential of HIV-1 escape and increases the possibil-
ity of HIV-1 excision despite the continuous mutations
in the clinical HIV-1 patients’ population [48]. Many
other therapies are currently ongoing to cure disease
such as haemoglobinopathy, β-thalassaemia, Leber con-
genital amaurosis, haemophilia giving hope to all pa-
tients that could not count on alternative therapy ways
[49–51]. Even on cancer research there are some en-
couraging studies. In the last few years, research focused
especially on those types of cancer that are untreatable
with standard chemo- or radiotherapies and in particular
the lung cancer, which is one of the most fatal and, even
if a lot of efforts have been spent, is still the main cause
of cancer-related deaths. Immunotherapy has emerged
as a promising way to treat lung cancer using thera-
peutic vaccines and targeting the specifically cytotoxic T
lymphocyte associated protein 4 and programmed death
receptor 1 (PD-1) pathways [52]. Lu You, an oncologist
at Sichuan University’s West China Hospital in Chengdu,
started testing modified immune T cells treating non-
small cell lung cancer for patient whose chemotherapy,
radiation therapy and other treatments have failed [53].
These T cells, which are PD-1 KO, once reintroduced in
patients will home in the tumor activating the immune
response and hopefully eradicating tumor cells. Indeed,
PD-1, also known as CD279, and its pathway is involved
in T-cells regulation and autoimmunity, so knocking it
out lead to a forced activation of the immunity system,
deleting the brakes that limit the immune response [54].
Similar trials with PD1‑knockout T cells for prostate,
bladder cancer, as well as renal cell carcinoma, are also
being initiated [55]. Other anticancer immune therapies
are recently emerged founded on the production of
next-generation chimeric antigen receptor (CAR) T cells
[56]. These cells, which express tumor-targeting recep-
tors, have shown promise in the treatment of various
leukaemias, lymphomas and solid cancers. CARs include
an extracellular binding domain which recognizes an
antigen that is highly specific and strongly expressed on
tumor cells, and an intracellular chimeric signalling do-
main that activates the T cells upon receptor engage-
ment. This mechanism promotes T cell-mediated killing
of tumor cells (Table 1).
In addition to the use described above, CRISPR-Cas
system has the potential to be used to regulate endogen-
ous gene expression or to label specific chromosomal
loci in living cells or organisms. Catalytically inactive or
“dead” Cas9 (dCas9) can be recruited by gRNAs to spe-
cific target DNA sites [57]. Targeting of dCas9 to pro-
moters was initially shown to repress gene expression in
both Escherichia coli and human cells [58–60]. It has
also been demonstrated that an EGFP-dCas9 fusion can
be used to visualize DNA loci harboring repetitive
sequences, such as telomeres, with a single gRNA or
non-repetitive loci using 26 to 36 gRNAs covering a 5-
kb region of DNA [61]. This imaging system provides a
powerful tool for studying chromosome dynamics and
structure. It is also really interesting to see whether
dCas9 fusions to histone modifiers and proteins involved
in altering DNA methylation, can also be used to per-
form targeted “epigenome editing”. Indeed, it was re-
cently found that many epigenetic factors are involved in
multiple types of cancer such as glioblastoma, chondro-
sarcoma and osteosarcoma [62–64], so targeting epigen-
etic regulatory enzymes may be one suitable way to
dysregulate tumor maintenance. As reported by Chen et
al. [65], dCas9 could be fused to transcriptional
activation domain such as VP64, VP64-p65-Rta,
Kruppel-associated box (KRAB), activating or repressing
selectively the target gene expression depending on the
strength of activator or repressor used and the target
transcription start site. In this way dCas9 might also be
used to interfere with transcriptional elongation, direct-
ing to the non-template strand of a gene, resulting in
10- to 300- fold repression of mRNA transcription or
when directed to a region which was initially occupied
by RNA polymerase, dCas9 could also inhibit transcrip-
tion initiation. CRISPR was also used to recreate muta-
tions commonly identified in patients’ tumors and assess
their effects in a cell line, to better understand the
tumor-driving mutations, their phenotypic effects and
then to identify new anticancer agents [66]. As reported
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by Matano et al. and Drost et al., it is possible to intro-
duce a series of single mutations to transform an intes-
tinal human organoid to an invasive carcinoma [67, 68]
demonstrating that four mutations (APC, KRAS,
SMAD4 and TP53) were mandatory to drive this process
and that APC and TP53 loss was sufficient to induce
chromosomal instability. Transducing a non-metastatic
mouse lung cancer cell line with a lentiviral CRISPR/
Cas9 library, targeting thousands of protein-coding
genes and hundreds of microRNA precursors and inocu-
lating these cells in immunodeficient mice, Chen et al.
formed several growing tumors and lung metastases.
The consequent deep sequencing analysis of the ran-
domized KO tumor cells enabled the identification of
several genes, whose inactivation may trigger tumor
growth and invasion [69]. The main discovery of this
kind of approach is that the selection of new tumor
markers does not imply previous knowledge of the dif-
ferent functional hallmarks acquired throughout tumori-
genesis. Another intriguing way to exploit CRISPR
system would be to target tumor markers directly inside
tumor site. In such a way it might be possible to over-
come the genetic mutations leading tumor proliferation
and metastatic capacity. However, in this approach the
main problem is that every single tumor bears different
mutation so it would require a very precise and person-
alized CRISPR therapy and another problem is the deliv-
ery system, because trying to make a selective gene
knock out only in tumor cells is practically impossible
with today technologies. An alternative target in cancer
treatment for CRISPR might be the miRNAs expression.
Indeed, miRNAs are involved in the regulation of a
plethora of cellular physiological and pathological pro-
cesses in a selective tissue-specific way [70], so the
selective knock out of a single miRNA can lead to a
powerful modulation of many genes at the same time.
As demonstrated by Chang et al. the CRISPR-mediated
knock out of miR-17, miR-200c and miR-141 in two
colon cancer cell is actually possible and the repression
could be stably maintained unaltered for a long term
period [71]. So, it might be also possible to modulate
miRNA expression with CRISPR technology in tumor-
associated immune cells, regulating their recruitment
and activation in the tumor microenvironment, waking
up the immune system against tumor cells as yet dem-
onstrated with the PD-1 KO [72]. The challenge for the
future will be for sure to find a secure and safe way to
delivery CRISPR machinery only in the tumor site and
to inhibit its proliferative and metastatic ability. How-
ever, this system even if fascinating is not error free as
yet reported above and so potential ethical concerns re-
lated to the impact of targeted nucleases upon cells
germline are under discussion. Moreover, CRISPR appli-
cation in vivo and especially in human has a very low
working efficiency, demonstrating that we need to fur-
ther improve our knowledge of this gene editing tool to
create really efficient and safe therapy for all the disease
related to a genetic mutation. Methods for expanding
the targeting range of RNA-guided Cas9 will be import-
ant for inducing precise HDR or NHEJ events as well as
for implementing multiplex strategies, including paired
nickases.
Conclusions
It is necessary to improve the reliability of the system in
order to reduce off-target effects and improvements will
be needed, particularly for therapeutic applications. Ex-
amples of such improvements might involve using
Table 1 Novel gene editing-based therapies
Disease Target Reference
Duchenne Muscular Dystrophy Dystrophin [38–40]
Cystic Fibrosis Cystic Fibrosis Transmembrane Conductance Regulator [41]
HPV E6 & E7 [42;43]
HBV HBsAg & HBx [44]
EBV EBNA1, EBNA3C & LMP-1 [45]
BART miRNA [46]
AIDS Gag/Pol - Rev/Env [47]
LTR-1, LTR-3, GagD & PolB [48]
β-thalassaemia β-/γ-globin [49]
Leber congenital amaurosis CEP290 [50]
Haemophilia F9 [51]
Non-small Cell Lung Cancer PD-1 [53]
Prostate Carcinoma PD-1 [55]
Bladder Carcinoma PD-1 [55]
On the left column it is reported the disease, on the central one the target gene and on the right one the reference number
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protein engineering to modify Cas9 and/or modifying
the nucleotides used by the gRNA to mediate recogni-
tion of the target DNA site. Alternatively, the construc-
tion of inducible forms of Cas9 and/or gRNAs might
provide a means to regulate the active concentration of
these reagents in the cell and thereby improve the ratio
of on- and off-target effects. The simplicity, high effi-
ciency and broad applicability of the RNA-guided Cas9
system have positioned this technology to transform bio-
logical and biomedical research. The ease with which re-
searchers can now make changes in the sequence or
expression of any gene means reverse genetics can be
performed in virtually any organism or cell type of inter-
est. All of these recent advances—and those to come—in
developing and optimizing Cas9-based systems for gen-
ome and epigenome editing should propel the technol-
ogy toward therapeutic applications, opening the door to
treating a wide variety of human diseases.
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